BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1214. [PMID: 32413973 DOI: 10.3390/cancers12051214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Decarli K, Strosberg J, Almhanna K. Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. Cancers 2022;14:4201. [DOI: 10.3390/cancers14174201] [Reference Citation Analysis]
2 Jin H, Amonkar M, Aguiar-Ibáñez R, Thosar M, Chase M, Keeping S. Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, microsatellite instability-high or mismatch repair-deficient colorectal cancer. Future Oncol 2022. [PMID: 35332802 DOI: 10.2217/fon-2021-1633] [Reference Citation Analysis]
3 Sakata S, Larson DW. Targeted Therapy for Colorectal Cancer. Surgical Oncology Clinics of North America 2022. [DOI: 10.1016/j.soc.2021.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Persano M, Puzzoni M, Ziranu P, Pusceddu V, Lai E, Pretta A, Donisi C, Pinna G, Spanu D, Cimbro E, Parrino A, Liscia N, Mariani S, Dubois M, Migliari M, Scartozzi M. Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Rev Anticancer Ther 2021;21:1253-64. [PMID: 34551663 DOI: 10.1080/14737140.2021.1982699] [Reference Citation Analysis]
5 Zou Y, Zhang J, Zhang L, Yan X. Interferon-induced protein 16 expression in colorectal cancer and its correlation with proliferation and immune signature markers. Oncol Lett 2021;22:687. [PMID: 34434286 DOI: 10.3892/ol.2021.12948] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Liu N, Shan F, Ma M. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. Int Immunopharmacol 2021;99:108017. [PMID: 34352568 DOI: 10.1016/j.intimp.2021.108017] [Reference Citation Analysis]
7 Lai E, Puzzoni M, Ziranu P, Cremolini C, Lonardi S, Banzi M, Mariani S, Liscia N, Cinieri S, Dettori M, Mencoboni M, Nappo F, Piacentini G, Labianca R, Zucchelli G, Boccaccino A, Conca V, Pusceddu V, Zaniboni A, Scartozzi M. Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study. Clinical Colorectal Cancer 2021. [DOI: 10.1016/j.clcc.2021.07.008] [Reference Citation Analysis]
8 Zhu X, Zhu J, Tan T, Bu F, Zhao J, Luo C, Luo H. RP11-51O6.1 sponges miR-206 to accelerate colorectal cancer carcinogenesis and metastasis through upregulating YAP1. Carcinogenesis 2021;42:984-94. [PMID: 34038520 DOI: 10.1093/carcin/bgab044] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Ziranu P, Lai E, Schirripa M, Puzzoni M, Persano M, Pretta A, Munari G, Liscia N, Pusceddu V, Loupakis F, Demurtas L, Libertini M, Mariani S, Migliari M, Dubois M, Giampieri R, Sotgiu G, Dei Tos AP, Lonardi S, Zaniboni A, Fassan M, Scartozzi M. The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. Target Oncol 2021;16:517-27. [PMID: 33970400 DOI: 10.1007/s11523-021-00816-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lai E, Cascinu S, Scartozzi M. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Front Oncol 2021;11:637823. [PMID: 34041019 DOI: 10.3389/fonc.2021.637823] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Rovesti G, Marisi G, Casadei-Gardini A. Recent Research on Gastrointestinal Carcinoma. Cancers (Basel) 2021;13:333. [PMID: 33477500 DOI: 10.3390/cancers13020333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jin K, Ren C, Liu Y, Lan H, Wang Z. An update on colorectal cancer microenvironment, epigenetic and immunotherapy. Int Immunopharmacol 2020;89:107041. [PMID: 33045561 DOI: 10.1016/j.intimp.2020.107041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ismail NI, Othman I, Abas F, H Lajis N, Naidu R. The Curcumin Analogue, MS13 (1,5-Bis(4-hydroxy-3- methoxyphenyl)-1,4-pentadiene-3-one), Inhibits Cell Proliferation and Induces Apoptosis in Primary and Metastatic Human Colon Cancer Cells. Molecules 2020;25:E3798. [PMID: 32825505 DOI: 10.3390/molecules25173798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
14 Janssen E, Subtil B, de la Jara Ortiz F, Verheul HMW, Tauriello DVF. Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1875. [PMID: 32664619 DOI: 10.3390/cancers12071875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]